Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates

Anaerobe

Volumn 31, Issue , 2015, Pages 47-49

  Eitel, Zsuzsa ^a   Terhes, Gabriella ^a   Sóki, József ^a   Nagy, Elisabeth ^a   Urbán, Edit ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antibiotic susceptibility; Clostridium difficile; Fidaxomicin

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; IC50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; DRUG EFFECTS; HUNGARY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

CLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; HUNGARY; MICROBIAL SENSITIVITY TESTS;

EID: 84922698561     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.08.002     Document Type: Article

References (14)

1. Kelly C.P., LaMont J.T. Clostridium difficile: more difficult than ever. NEngl J Med 2008, 359:1932-1940.
2. Al-Nassir W.N., Sethi A.K., Li Y., Pultz M.J., Riggs M.M., Donskey C.J. Both oral metronidazole and oral vancomycin promote persistant overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.
3. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005, 5:549-557.
4. Sears P., Ichikawa Y., Ruiz N., Gorbach S. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Ann N Y Acad Sci 2013, 1290:33-41.
5. Kato N., Ou C.Y., Kato H., Bartley S.L., Brown V.K., Dowell V.R., et al. Identification of toxigenic Clostridium difficile by the polymerase chain reaction. J Clin Microbiol 1991, 29:33-37.
6. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000, 186:307-312.
7. Terhes G., Urbán E., Sóki J., Szikra L., Konkoly-Thege M., Vollain M., et al. Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrheal patients in Hungary. Anaerobe 2008, 15:237-240.
8. Terhes G., Urbán E., Konkoly-Thege M., Székely É., Brazier J.S., Kuijper E.J., et al. First isolation of Clostridium difficile PCR ribotype 027 from a patient with severe persistent diarrhoea in Hungary. Clin Microbiol Infect 2009, 15:885-886.
9. Clinical and Laboratory Standards Institute Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-sixth ed 2007, Document M11-A7, CLSI, Wayne, PA.
10. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, 51:2716-2719.
11. Citron D.M., Babakhani F., Goldstein E.J.C., Nagaro K., Sambol S., Sears P., et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009, 15:234-236.
12. Goldstein E.J.C., Babakhani F., Citron D.M. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012, 55(Suppl.2):S143-S148.
13. Rashid M.U., Dalhoff A., Weitraub A., Nord C.E. Invitro activity of MCB3681 against Clostidium difficile strains. Anaerobe 2014, 28:216-219.
14. Leeds J.A., Sachdeva M., Mullin S., Barnes S.W., Ruzin A. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 2014, 69:41-44.